

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

March 28, 2017

| | | |
|-------------------------------|---|----------------------------|
| IN THE MATTER OF | : | |
| | : | |
| NewGen BioPharma Corp. | : | ORDER OF SUSPENSION |
| | : | OF TRADING |
| File No. 500-1 | : | |

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of NewGen BioPharma Corp. (CIK No. 0001537274) because of questions regarding the accuracy and adequacy of publicly available information, in periodic and other reports, about the company since at least January 9, 2014, specifically (i) the identity of its former sole executive officer, director, and majority shareholder; and (ii) possible undisclosed former and current controlling persons. NewGen BioPharma Corp. is a Nevada corporation whose current principal place of business is in Seattle, Washington. Its stock is quoted on OTC Link LLC, operated by OTC Markets Group, Inc., under the ticker symbol NEWG.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT, on March 28, 2017 through 11:59 p.m. EDT, on April 10, 2017.

By the Commission.

Brent J. Fields
Secretary